Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study.

Hernando Knobel Esperanza Cañas-Ruano Ana Guelar Pablo Knobel Judit Villar-GarcíaAlicia González-MenaCeclia Canepa Itziar Arrieta-Aldea Augustin MarcosAgustí Abalat-TorrresRoberto Güerri-Fernandez

Published in: HIV research & clinical practice (2023)

Switching to either B/T/F or D/L treatment for PLWH was effective and well tolerated in this real-world study. Treatment discontinuation rates did not significantly differ between the two regimens.

Keyphrases

hiv infected patients
antiretroviral therapy
combination therapy
replacement therapy
smoking cessation